Refine by
Disease Resistant Articles & Analysis
37 news found
The Centers for Disease Control and Prevention describe Methicillin-resistant Staphylococcus aureus (MRSA) as a type of staph that can be resistant to several antibiotics. ...
The Centers for Disease Control and Prevention describe Methicillin-resistant Staphylococcus aureus (MRSA) as a type of staph that can be resistant to several antibiotics. ...
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. With the rise of antibiotic-resistant bacteria posing a significant threat to global public health, ...
The applications of WGS are vast, impacting fields such as disease research, drug discovery, personalized medicine, food safety, agriculture, and pharmacy. ...
The company launches the drug-resistant metabolomics research service for oncology research and infectious disease studies regarding drug resistance. ...
By using Leaf’s proprietary transient expression technology Supravec®, in partnership with Professor Mark Banfield’s lab at the John Innes Centre, the team will explore the mechanistic biology of plant proteins involved in pathogen recognition and disease resistance. The research led by Professor Banfield’s group at the John Innes Centre ...
The role of the immune system and inflammation in Alzheimer’s disease has been broadly known for years but it is becoming increasingly clear that effective management of AD may require anti-inflammatory strategies. ...
TOPICS 2022: The diagnostic laboratory in 2032: reflecting medical needs in changing health systems Infectious diseases: detecting resistance on various levels Cancer & Co. – diagnostics for complex diseases AI & Digital diagnostics ...
Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces the appointment of Alexandra Clyde as an independent Non-Executive Director of the Company. ...
(Nasdaq: MCRB), a leading microbiome therapeutics company, will present preclinical findings tomorrow at the European Bone Marrow Transplantation (EBMT) Annual Meeting that suggest SER-155 works by targeting the host immune response, potentially allowing patients undergoing hematopoietic stem cell transplantation (HSCT) to avoid infection or Graft-versus-Host Disease (GvHD), ...
The Company also today announced the completion of enrollment in its 12-week Phase 1b clinical trial of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD). The 48-week MOMENTUM trial is being conducted at approximately 25 sites in the United States with Dr. ...
” The FDA’s Breakthrough Device Program is designed to give patients more timely access to novel technologies, like the Monarch eTNS System, that provide more effective treatments for life-threatening or irreversibly debilitating human diseases and conditions. Drug-resistant epilepsy (DRE) occurs in approximately 30% of epilepsy patients, resulting ...
Whole transcriptome sequencing has a wide range of applications, such as growth and development regulation (including animal metamorphosis, plant flowering, fruit development, etc.), environmental adaptation mechanisms (including drought, salt tolerance, disease resistance, etc.), immune interaction (including bacteria, fungus, virus infection). ...
The importance of IOP reduction to limit or halt disease progression is well known and has been demonstrated in landmark studies such as the Advanced Glaucoma Intervention Study (AGIS) and the Early Manifest Glaucoma Trial (EMGT). ...
SAGAsafe® is part of a portfolio of ultrasensitive technologies, which also includes SAGAsign® for personalized monitoring of cancer burden and minimal residual disease (MRD) using chromosomal rearrangements, as well as novel technologies in development. ...
The TRACERx study focuses on cancer evolution in lung cancer patients and tracking the evolutionary trajectory of the disease from diagnosis through to relapse. The PEACE study accepts post-mortem tissue donation for comprehensive cancer research with the aim to benefit future patients. ...
“AVM0703 represents an entirely new approach for cancer and non-cancerous diseases. It has the potential to be a true game-changer. I am encouraged by the pre-clinical data and look forward to seeing results of this pivotal trial,” said Dr. ...
“Eliminating the need for daily insulin could transform disease management for the hundreds of millions of people across the world suffering from type 2 diabetes. ...
” “Fractyl's founding mission was to find a better way to treat type 2 diabetes by addressing the root cause of disease that can reverse the disease process rather than manage its symptoms. ...
Founded on great experience built up at international level in the cleaning of environments in which pathogens spread in the past (from influence to infective diseases resistant to antibiotics), the GBAC STAR™ program will enable to establish and maintain control based on the training and accountability of IEG´s management and employees on the ...